The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Budman
Daniel R
DR
Division of Medical Oncology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA. budman@nshs.edu
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001711:Biotransformation; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000077143:Docetaxel; D004334:Drug Administration Schedule; D015195:Drug Design; D004357:Drug Synergism; D004790:Enzyme Induction / Q000187:drug effects; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D000077146:Irinotecan; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D043823:Taxoids; D013939:Thymidine Phosphorylase / Q000378:metabolism; D059004:Topoisomerase I Inhibitors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D003841:Deoxycytidine; D000077143:Docetaxel; D015251:Epirubicin; D000069287:Capecitabine; D000077146:Irinotecan; D013939:Thymidine Phosphorylase; D017239:Paclitaxel; D005472:Fluorouracil; D002166:Camptothecin